Trial Profile

Evaluation of Bone Quality in Patients With Rheumatoid Arthritis Treated With Baricitinib: Single Centre, Mode of Action Study (BARE BONE)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms BAREBONE

Most Recent Events

14 Nov 2022 Results assessing the changes in bone strength in patients with active rheumatoid arthritis under baricitinib treatment using µFEA on the radial bone, presented at the ACR Convergence 2022.
04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
14 Jan 2021 Planned End Date changed from 11 Sep 2020 to 11 Oct 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com